E-cigarette Sales Surge by Almost 50%: CDC Data

Jun.25.2023
E-cigarette Sales Surge by Almost 50%: CDC Data
CDC data shows e-cigarette sales increased nearly 50% in three years, led by non-tobacco flavors. Sales of disposable e-cigarettes surpassed pod systems.

According to CBS News, data released by the U.S. Centers for Disease Control and Prevention (CDC) shows that e-cigarette sales have grown by nearly 50% over the past three years, increasing from 15.5 million in January 2020 to 22.7 million in December 2022.


These data come from an analysis by the Centers for Disease Control and Prevention of data from market research companies. The analysis was published in the agency's "Morbidity and Mortality Weekly Report.


One-time-use sales surpass replaceable magazine sales.


Fatma Romeh, the Chief Market Analyst at CDC, stated in a declaration that...


The significant increase in e-cigarette sales from 2020 to 2022 is primarily driven by the growth of non-tobacco flavored e-cigarettes, such as the dominance of mint flavor in the prefilled pod market and the leading position of fruit and candy flavors in the disposable e-cigarette market.


According to the national youth tobacco survey data released in 2022, more than 80% of middle and high school students use e-cigarettes with fruit or mint flavors, as pointed out by Romei.


According to data, even though disposable e-cigarettes accounted for less than a quarter of total sales in January 2020, by March 2022 disposable e-cigarette sales surpassed pod system sales.


From January 2020 to December 2022, the unit share of pod systems decreased from 75.2% of total sales to 48.0%, while the unit share of disposable e-cigarettes increased from 24.7% to 51.8%.


Sales of e-cigarettes | Image source: Centers for Disease Control and Prevention in the United States


Sales volume of pod systems | Image source: Centers for Disease Control and Prevention in the United States.


Sales of disposable e-cigarettes | Image source: Centers for Disease Control and Prevention in the United States.


The total number of e-cigarette brands in the market has increased by 46.2%.


According to data, the number of e-cigarette brands in the United States market is continually increasing. During the CDC study, the total number of e-cigarette brands in the US market increased by 46.2%, from 184 to 269.


Deirdre Lawrence Kittner, the Director of Smoking and Health Office at the CDC, stated in a release:


The sharp rise in e-cigarette use among teenagers in 2017 and 2018, fueled largely by JUUL, highlights the rapid evolution of sales and use patterns in the e-cigarette industry.


The overall sales growth of e-cigarettes has slowed down.


According to data, total sales increased by 67.2% from January 2020 to May 2022, rising from 15.5 million units per period to 25.9 million units. However, from May 2022 to December 2022, total sales decreased by 12.3%.


Even though overall monthly sales have been decreasing since May 2022, sales are still millions higher compared to early 2020. The CDC attributes the recent decline to several factors, including the efforts of health departments to regulate the sales of nicotine products.


At the national level, the FDA has taken multiple measures this year in an effort to curb unauthorized sales of e-cigarettes.


Director of the Center for Tobacco Products (CTP) at the FDA, Brian King, stated in a declaration that:


All participants in the supply chain, including retailers, have a responsibility to prevent illegal e-cigarettes from being placed on the market.


A previous CDC study report analyzed that the comprehensive flavor ban in Massachusetts resulted in a sharp decline of 94% in the sales of flavored e-cigarettes in the state.


It is worth noting that more and more state and local governments in the United States are also attempting to impose restrictions on the sale of flavored e-cigarettes.


As of December 31, 2022, seven states (California, Maryland, Massachusetts, New Jersey, New York, Rhode Island, and Utah) and 378 jurisdictions (including counties, cities, towns, and villages) have implemented some form of restriction on flavored electronic products.


The CDC acknowledged that other factors may also contribute to the sales slowdown, including the increase in high-dose or high-volume disposable e-cigarettes purchased at one time, resulting in more or stronger doses each time.


Moreover, this data is limited to the sales performance of traditional brick-and-mortar retailers. This suggests that some sales may not have actually declined, but instead shifted elsewhere, such as online orders or specialized e-cigarette stores not included in the company's sales data.


References:


Health officials have raised concerns about the surge in e-cigarette sales, which have coincided with a rise in calls to poison control centers.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Swedish Match Faces Broader Labeling Order After ZYN Inspection, Documents Obtained by 2Firsts Show
Swedish Match Faces Broader Labeling Order After ZYN Inspection, Documents Obtained by 2Firsts Show
Documents obtained by 2Firsts show that Sweden's Public Health Agency ordered Swedish Match to revise ingredient labels beyond the five ZYN products inspected. The dispute centers on whether flavoring ingredients must be individually disclosed, with Swedish Match citing trade-secret protection and the regulator insisting on full ingredient disclosure. The company faces a conditional penalty of SEK 2 million per month for noncompliance. As of October 22, the agency had received no appeal, despite the company's stated intention to challenge the decision.
Oct.22
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules
UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules
The UK’s Vaping Products Duty and Vaping Duty Stamps Scheme will take effect on October 1, 2026. All vaping liquids manufactured in or imported into the UK will face a flat excise duty of £2.20 per 10ml, whether or not they contain nicotine. Newly manufactured or imported products released onto the UK market from October 1 will require a valid duty stamp, while eligible existing unstamped inventory can continue to be sold through March 31, 2027. From April 1, 2027, all vaping products outside duty suspension must carry a valid stamp.
Sep.03
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03